Advanced management of ventricular arrhythmias in chronic Chagas cardiomyopathy

David Santacruz, MD,† Fernando Rosas, MD,*† Carina Abigail Hardy, MD,‡
Diego Ospina, MD,† Andrea Nathalie Rosas, MD,† Juan Manuel Camargo, MD,*†
Juan José Bermúdez, MD,*† Juan Felipe Betancourt, MD,*,† Victor Manuel Velasco, MD,*,†
Mario D. González, MD, FHRS*‡

From the *Department of Cardiac Electrophysiology, Fundación Clínica Shaio, Bogotá, Colombia,
†Training Program in Cardiac Electrophysiology, Pontificia Universidad Javeriana, Bogotá,
Colombia, ‡Arrhythmia Unit, Heart Institute (InCor), University of Sao Paulo Medical School, Sao
Paulo, Brazil, †Medicine Training Program, Universidad del Rosario, Bogotá, Colombia, and*†Clinical
Electrophysiology, Hershey Medical Center, Penn State University, Hershey, Pennsylvania.

Chagas cardiomyopathy is a parasitic infection caused by Trypanosoma cruzi. Structural and functional abnormalities are the result of direct myocardial damage by the parasite, immunological reactions, dysautonomia, and microvascular alterations. Chronic Chagas cardiomyopathy (CCC) is the most serious and important manifestation of the disease, affecting up to 30% of patients in the chronic phase. It results in heart failure, arrhythmias, thromboembolism, and sudden cardiac death. As in other cardiomyopathies, scarrelated reentry frequently results in ventricular tachycardia (VT). The scars typically are located in the inferior and lateral aspects of the left ventricle close to the mitral annulus extending from endocardium to epicardium. The scars may be more prominent in the epicardium than in the endocardium, so epicardial mapping and ablation frequently are required. Identification of late potentials during sinus rhythm and mid-diastolic potentials during hemodynamically tolerated VT are the main targets for ablation. High-density mapping during sinus rhythm can identify late isochronal regions that are then targeted for ablation. Preablation cardiac magnetic resonance imaging with late enhancement can identify potentials areas of arrhythmogenesis. Therapeutic alternatives for VT management include antiarrhythmic drugs and modulation of the cardiac autonomic nervous system.

KEY WORDS Antiarrhythmic treatment; Cardiomyopathy; Catheter ablation; Chagas disease; Endo-epicardial approach; Implantable cardioverter-defibrillator; Neuraxial modulation; Ventricular tachycardia

(Heart Rhythm O2 2021;2:807–818) © 2021 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction and epidemiology
Chagas disease is a zoonosis caused by the parasite Trypanosoma cruzi, which is transmitted to humans mainly by triatomine insects. Other less common routes of infection include oral transmission, transfusion of contaminated blood products, organ transplantation, and during delivery. The disease is endemic in South and Central America. Its prevalence is approximately 6–7 million individuals, resulting in 21,000 deaths each year. It is currently an emerging health problem in countries such as the United States, Europe, Japan, and Australia, mainly due to global migration. In addition, autochthonous vector transmissions of T. cruzi in the southern states of the United States has been documented in several cases. Chronic Chagas cardiomyopathy (CCC) develops in up to 30% of patients in the chronic phase and can lead to heart failure (HF), arrhythmias, thromboembolism, and sudden cardiac death (SCD). Globally, CCC is the most common cause of dilated cardiomyopathy not related to coronary or valvular disease. The purpose of this article is to review CCC-related ventricular arrhythmias.

Pathogenesis of Chagas cardiomyopathy
The pathogenic mechanisms involved in CCC include direct myocardial damage by the parasite, immunological alterations, dysautonomia, and microvascular lesions. The current consensus is that persistence of T. cruzi is directly related to cell death and the induced immune response. For this reason, CCC is considered an acquired inflammatory cardiomyopathy in which the parasite load is directly related to the intensity of the inflammation and the severity of the disease. A mechanism of molecular mimicry between parasite epitopes and host antigens favors a crossover autoimmune response. Chronic T. cruzi infection causes direct autonomic nerve damage, leading to neuronal loss...
Pathophysiology of arrhythmias in Chagas cardiomyopathy

It is well established that the mechanism of sustained ventricular tachycardia (VT) in CCC is scar-related reentry.\textsuperscript{27–29} The main arrhythmogenic substrates in CCC are necrotic and fibrotic lesions secondary to chronic myocarditis.\textsuperscript{5,14} The inflammatory process results in dense scars within which some surviving myocytes are arranged. These changes cause alterations in the electrical coupling that result in slow conduction, unidirectional block, and development of reentrant circuits.\textsuperscript{30–32} Coexistence of denervated areas in the injured myocardium could result in ventricular arrhythmias and SCD during sympathetic activation.\textsuperscript{33,34} In some patients, the presence of surviving myocardium between the mitral valve and scar area can behave as a conducting isthmus, allowing the development of a macroreentrant circuit.\textsuperscript{35}

The left ventricle (LV) is the site of origin of sustained VT in more than 90% of cases. The main arrhythmic substrate of the LV is located in the basal inferolateral region in approximately 70%–82% of patients and in the apical region. This may be the result of ischemia caused by low coronary distal perfusion pressure.\textsuperscript{36–38}

An interesting feature of CCC is that myocardial scars tend to be larger in the epicardium compared to the endocardium, and many patients have a high prevalence of epicardial circuits. In 1 study, electroanatomical mapping showed larger low-voltage areas on the epicardial surface compared to the endocardium (112 ± 74 cm\textsuperscript{2} vs 61 ± 22 cm\textsuperscript{2}; \( P = .01 \)), with 82% of patients having larger epicardial scars.\textsuperscript{27–29}

Diagnostic evaluation of ventricular arrhythmias in Chagas cardiomyopathy

CCC may be associated with certain characteristics useful in the differential diagnosis with other cardiomyopathies that could help improve detection in patients with VT of uncertain etiology. Table 1 summarizes the clinical characteristics that increase the index of suspicion for CCC in patients with ventricular arrhythmias.\textsuperscript{5,39–41}

ECG

The ECG is a useful tool for screening patients for CCC due to its high sensitivity (83%) and negative predictive value (96%).\textsuperscript{42} The test is inexpensive, is available worldwide, and together with the clinical evaluation represents the first step to the evaluation of these patients.

The most frequent abnormalities are right bundle branch block, left anterior fascicular block, polymorphic premature ventricular complexes, and abnormal ventricular repolarization. In addition, sinus nodal dysfunction, atrioventricular block, and atrial fibrillation are frequently observed. As expected, the prevalence of ECG abnormalities varies according to the population studied.\textsuperscript{43,44} Abnormalities in the intraventricular conduction system are a marker of myocardial damage in Chagas disease. Nevertheless, it is important to clarify that no single ECG finding is pathognomonic for CCC. The right bundle is more sensitive to damage because of its length and therefore is the most frequently affected, followed by the anterior division of the left bundle (Figure 1). Hence, right bundle branch block is the most prevalent and specific ECG abnormality when found in individuals with Chagas disease, with a positive predictive value of 80.77% (95% confidence interval [CI] 78.17–83.13).\textsuperscript{43,45,46}

A normal ECG, of course, does not exclude myocardial damage. Intravenous administration of ajmaline can mask latent conduction disturbances in one-third of patients with Chagas disease without evidence of cardiac involvement.\textsuperscript{37} However, observational studies have shown that people with normal ECG and positive Chagas disease serology have a good prognosis after 5 to 10 years of follow-up.\textsuperscript{48,49} Finding \textit{de novo} abnormalities on the ECG helps to identify patients with reduced LV ejection fraction. The duration of the QRS complex is also directly related to ventricular size and is inversely proportional to LV ejection fraction. The greater the number of ECG alterations found in the same patient, the greater the myocardial involvement and the worse the prognosis.\textsuperscript{5,50,51} The increase in the duration of the QRS complex or the development of new ECG changes are sufficient reasons to re-evaluate ventricular function.\textsuperscript{52}
Holter ECG monitoring

Documentation of premature ventricular contractions is a common finding (10%–55%) in patients with CCC. Its presence is attributed to myocardial damage and is correlated with the recording of late potentials in the signal-averaged ECG. In patients with CCC having abnormal resting ECG and HF, premature ventricular contractions are observed in up to 99%, which can be polymorphic (87%) and manifest with repetitive phenomena such as duplets or in episodes of nonsustained ventricular tachycardia (NSVT).60,61

Magnetic nuclear resonance

Cardiac magnetic resonance imaging (MRI) provides excellent spatial resolution useful for recognizing structural cardiac changes not identified by other imaging techniques. Furthermore, the use of late gadolinium enhancement can identify the presence of areas of fibrosis and edema, even in indeterminate cases (Figure 2). The extent of myocardial fibrosis is directly correlated with the severity of the disease and inversely with LV ejection fraction.54-56 MRI makes it possible to precisely delineate the dense scar and visualize the corridors of viable tissue that may support VT.57 Patients with ≥2 contiguous segments of transmural fibrosis are more likely to have VT (relative risk [RR] 4.1; P = .04).56,58 For their identification, special image processing software has been implemented, which includes MRI and computed tomography (Figure 3). Finally, the presence and area of the scar are strong predictors of VT and mortality.59

Electrophysiological study

An electrophysiological study is indicated in symptomatic patients, in those with conduction abnormalities or VT, or in patients with reduced LV function. Patients with conduction disturbances in the ECG, compromised ventricular function, or ventricular aneurysms are more likely to have inducible VT during the study.60

CCC and risk of SCD

The severity of ventricular arrhythmias in CCC usually are related to the degree of ventricular dysfunction; however, they also can be found in patients with preserved ventricular function, constituting an “isolated arrhythmic form” of the disease.51 This feature distinguishes CCC from other forms of heart diseases and explains why these patients are more susceptible to early SCD.5,12

MRIs with late enhancement have shown that the severity of ventricular arrhythmias correlate with the presence of scars and fibrosis.54,56 In addition, regional sympathetic denervation as observed with 123I-metaiodobenzylguanidine identifies an arrhythmic substrate.62,63

SCD is considered the main cause of mortality in patients with CCC and can account for 55%–65% of cases.7,12,64 More recently, observational studies suggest a reduction in mortality with the use of beta-blockers.65,66

Table 1  Clinical features that increase the index of suspicion for chronic Chagas heart disease in patients with ventricular arrhythmias

| Demographic         | Predominantly male |
|---------------------|--------------------|
| Age at diagnosis    | 30–50 y            |
| Epidemiological background | Origin or childhood residence in Latin America |
|                     | Children of mothers from endemic zones |
|                     | Travelers who spend time in endemic areas |
|                     | Blood transfusion (recipient of organ transplant) |
| Concomitant clinical manifestations | Palpitations, syncope, thoracic pain |
|                      | Thromboembolic events |
|                      | Biventricular or predominantly right ventricular dysfunction |
|                     | Compromise of other systems |
|                     | Megacolon |
|                     | Megaesophagus |
| Common ECG abnormalities | RBBB ± LAFB |
|                      | Frequent polymorphic premature ventricular contractions |
|                      | NSVT |
|                      | ST-T changes (mimicking ischemic heart disease) |
|                      | Abnormal Q waves |
|                      | Atrioventricular block |
|                      | Sinus nodal dysfunction |
|                      | Atrial fibrillation |
| Common echocardiographic findings | Left ventricular aneurysm in the apex or inferolateral wall |
|                      | Dilated cardiomyopathy |
|                      | Segmental abnormalities of myocardial contraction |
|                      | Right ventricular enlargement with reduced contractility |
|                      | Mural thrombus |
|                      | Cardiac magnetic resonance imaging |
|                      | Late apical and inferolateral enhancement |
|                      | Dilated cardiomyopathy ± ventricular perfusion defects/segmental abnormalities of myocardial contraction |
| Findings in perfusion scintigraphy | Perfusion defects without significant coronary artery obstruction |

ECG = electrocardiography; LAFB = left anterior fascicular block; NSVT = nonsustained ventricular tachycardia; RBBB = right bundle branch block.

Treatment and prognosis

Benznidazole and nifurtimox are the only antitrypanosomal drugs with proven efficacy. In accordance with the 2018 American Heart Association Scientific Statement on Chagas Cardiomyopathy, benznidazole is the first-line treatment because it has better tolerance, is more widely available, and is the best studied drug. Treatment is indicated in all patients with acute Chagas disease as soon as parasitological or serological confirmation is obtained, with parasite elimination and cure achieved in 60% to 90%. Success is high in cases of congenital transmission, achieved in >90% of infants treated during the first year of life.5,67-69 The role and efficacy of these medications in CCC are less certain. Trypanocidal treatment in patients with established Chagas cardiomyopathy was assessed in the landmark BENznidazole Evaluation For Interrupting Trypanosomiasis (BENznidazole Evaluation For Interrupting Trypanosomiasis) trial. The study randomized 2854 patients from 5 endemic countries in Central and South America to benznidazole or placebo. After mean follow-up of 5.4 years, a clear reduction in parasite detected by
polymerase chain reaction was documented; however, there was no difference in the primary composite outcome, which included death, HF, and other clinically relevant cardiovascular events. Comparative data from observational studies suggest that the prognosis of patients with HF due to CCC is less favorable and the mortality rate higher than in patients with other etiologies of HF. In CCC, all-cause mortality at 1, 5, and 10 years of follow-up is estimated at 12%, 35%, and 60%, respectively. As mentioned in the section on CCC and risk of SCD, in up to 65% of patients the final event is related to SCD, 25%–30% to progressive HF, and 10%–15% to stroke. The main risk factors associated with mortality are VT, HF, LV dilation, and/or systolic dysfunction. Different variables related to the risk of death have been evaluated in patients with CCC. In a study conducted in 424 patients with CCC using a separate validation cohort of 153 patients, 6 predictors were identified and are now part of the Rassi score: New York Heart Association (NYHA) functional class III or IV (5 points); cardiomegaly (5 points); segmental or global LV systolic dysfunction on electrocardiogram, and other cardiac biomarkers.

Figure 1   Electrocardiogram of a patient with chronic Chagas cardiomyopathy showing a right bundle branch block and a left anterior fascicular block.

Figure 2   Cardiac magnetic resonance imaging (MRI) in a patient with chronic Chagas cardiomyopathy. A: An enlarged left ventricle can be seen in cine MRI sequence. After administration of gadolinium, the presence of late enhancement with transmural extension is observed in the short (B), long parasternal (C), and four-chamber (D) axes, indicating the presence of fibrosis at the level of the anterior wall, in the middle and basal segments of the inferolateral and anterolateral walls, and in the basal segment of the inferior wall (arrows).
echocardiogram (3 points); NSVT on 24-hour Holter or stress test (3 points); low QRS voltage on 12-lead ECG (voltage in each limb lead ≤0.5 mV) (2 points); and male gender (2 points). With the resulting score, patients are classified into 3 groups: low risk (0–6 points); intermediate risk (7–11 points); and high risk (12–20 points). Five-year mortality in these groups is 2%, 18%, and 63%, respectively.74 Subsequently, Ribeiro et al53 developed a predictive score made up of 3 risk factors: reduced ejection fraction, VT, and prolonged filtered QRS complex. The score showed optimal discrimination to identify patients at low, moderate, and high risk of death, comparable to the score by Rassi et al.73 Subsequently, de Souza et al75 developed a risk score for SCD, based on 4 risk factors encompassing premature ventricular complexes, severe LV dysfunction, syncope, and QT dispersion by ECG. The score demonstrated good performance in predicting the risk of SCD, which is the most common cause of death overall in patients with Chagas disease.75

A simple scale recently published for predicting 2-year mortality risk in Chagas cardiomyopathy is the SaMI-TROP (São Paulo-Minas Gerais Tropical Medicine Research Center) score, which was developed and validated to be used in remote areas with limited technological resources. The score includes abnormal N-terminal pro-B-type natriuretic peptide (NT-proBNP) (55 points); QRS duration ≥150 ms (15 points); NYHA functional class higher than I (15 points); age (per 10 years); and heart rate ≥80 bpm (20 points). Abnormal NT-proBNP adjusted by age was the strongest predictor of death. A low-risk score was set as a predicted probability of dying in 2 years <2% (<50 points); intermediate risk was ≥2% to 10% (50–100 points), and the high-risk category had predicted risk of >10% (>100 points).76

Antiarrhythmic treatment
Recommendations for antiarrhythmic management in patients with CCC are based on observational data and are extrapolated from the results of studies in the management of cardiac diseases of other etiologies. Because ventricular arrhythmias in CCC usually are related to the presence of HF, optimal pharmacologic management of this clinical condition is essential.77 Amiodarone has been the most widely used drug for its multiple antiarrhythmic effects and its best safety profile in ventricular dysfunction. Furthermore, it has been attributed an apparent trypanocidal effect that may increase its efficacy.78–80 However, its potential toxicity must be taken into account, which includes liver injury, hypothyroidism or hyperthyroidism, and pulmonary toxicity.81 This drug is considered a therapeutic adjunct in patients with CCC who have an implantable cardioverter-defibrillator (ICD) with a history of recurrent VT.5,82,83

ICDs and Chagas cardiomyopathy
Patients with Chagas heart disease experience a higher rate of malignant ventricular arrhythmia and resultant SCD than other populations with dilated cardiomyopathy matched by
ventricular dysfunction.\textsuperscript{50,84} However, data supporting the use of ICDs for the treatment of patients with CCC are limited. Regarding the use of the ICD as a primary prevention strategy in patients with Chagas cardiomyopathy, there is no solid evidence based on randomized studies supporting its indication. Even when NSVT has been identified as an independent predictor of all-cause mortality and SCD in patients with CCC having LVEF between 30\% to 50\%, there is no clear guideline on the best strategy to follow. In this context, the prognostic role of programmed ventricular stimulation has been studied, and a significant association between inducible sustained VT and SCD has been found. Nevertheless, it is worth noting that in this study, all patients with induced sustained VT were treated with amiodarone.\textsuperscript{85} Although the use of ICDs has been recommended in patients with CCC and LVEF <40\%, a significant number of SCD occurs in patients with LVEF >40\%, and in these subjects there is no adequate way to establish their risk. Programmed ventricular stimulation may be an option, but new and larger studies are needed. The CHAGASICS trial (CHronic use of Amiodarone aGAInSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study) currently is underway to compare the use of amiodarone vs ICD implantation as a primary prevention strategy in patients with CCC.\textsuperscript{87}

The indication for ICD as a secondary prevention strategy does not differ from that established for other pathologies. According to the 2018 American Heart Association Scientific Statement on Chagas Cardiomyopathy, specific scenarios in which there is consensus on the benefit of ICD insertion for secondary prevention include patients with aborted SCD, spontaneous sustained VT, syncope secondary to VT, and LVEF <35\%, as well as a history of syncope and sustained inducible VT during an electrophysiological study.\textsuperscript{5,88}

Patients with CCC tend to present frequent effective ICD shocks due to their increased arrhythmic activity. The number of shocks received can be deleterious, contributing to mortality by inducing myocardial necrosis and promoting or worsening ventricular dysfunction.\textsuperscript{89} Combined administration of amiodarone and beta-blockers has contributed to reducing the number of therapies in other cardiomyopathies and should be considered in patients with CCC who receive frequent ICD shocks.\textsuperscript{82} Antiarrhythmic pacing strategies represent a safe, effective, and painless therapy for ventricular tachyarrhythmias, with a large body of clinical evidence supporting their routine use in primary and secondary ICD recipients, and could be considered in patients with CCC.\textsuperscript{80} Another recommendation is to perform ablation if possible before implanting an ICD. Other predictors of poor prognosis include LV ejection fraction <30\%, age >65 years, and low educational level.\textsuperscript{12}

**Mapping strategies and catheter ablation of VT**

Catheter ablation of VT is indicated in patients with drug-refractory monomorphic VT, those with an electrical storm (ES), and in patients suspected of having a discrete source of the arrhythmia.\textsuperscript{5,91,92} In a recent study of 38 patients with an ES who underwent catheter ablation, of whom 42.1\% had CCC, the procedure was associated with acute ventricular arrhythmia suppression in all patients. Freedom rates from ES and VT were 92.1\% and 60.5\%, respectively. Older patients and those with lower LVEF had increased mortality. Epicardial access was three times more frequent in patients with CCC (25\% vs 7.7\%). Patients with CCC were younger (60 vs 67 years; \( P = .033 \)), significantly more were women (50\% vs 9.1\%; \( P = .005 \)), and had higher LVEF (0.40 vs 0.28; \( P < .001 \)) than the other patients. Long-term outcome of CCC patients was similar to that of the overall population in terms of freedom from VT/ventricular fibrillation (62.5\% vs 59.1\%; \( P = .832 \)); freedom from ES (93.8\% vs 90.9\%; \( P = .748 \)); and overall mortality (25\% vs 31.8\%; \( P = .729 \)).\textsuperscript{93}

During the ablation procedure, a detailed electrophysiological study is required, in combination with high-density 3-dimensional maps (Figure 4). As mentioned in the section on Pathophysiology of arrhythmias in Chagas cardiomyopathy, the areas of fibrosis and scar tend to be located in the apical, inferolateral, and basal regions of the LV (Figure 5), with transmural or subepicardial substrates (Figure 6 and Supplemental Video 1). Occasionally, only an epicardial substrate can be identified. Cutoff values for bipolar voltage maps of both endo- and epicardial surfaces are identical to other forms of cardiomyopathy (bipolar amplitudes <0.5 mV: dense scar; 0.5–1.5 mV: areas of intermediate amplitudes defined as border zone; >1.5 mV: normal myocardium). Unipolar endocardial voltage may indicate an epicardial substrate in CCC patients with normal bipolar endocardial voltage or with a small endocardial scar. Cutoff values of 8.3 mV are used in patients with Chagas disease, similar to that for other cardiomyopathies.\textsuperscript{24,91} In relation to the duration of local electrograms, values >46 ms identify abnormal areas of slow conduction, with sensitivity and specificity of 83\% and 86\%, respectively.\textsuperscript{22} Placement of a multipolar electrode catheter in the coronary sinus can facilitate the diagnosis of submural reentry and epicardial late potentials. As in other cardiomyopathies, the strategy for VT ablation in Chagas disease varies with the number and morphology of induced VTs and their hemodynamic tolerance. When a hemodynamically tolerated VT is induced, the ablation target is mid-diastolic potentials that are part of the reentrant circuit as demonstrated with the entrainment technique. In patients in whom VT cannot be induced or is hemodynamically unstable, late potentials in the region of scar are identified and targeted for ablation and elimination of the reentrant circuits. Differential ventricular pacing may unmask late potentials that may not be obvious in sinus rhythm (Figure 5C). Once the electrograms with delayed components have been identified, a pacemapping strategy can be performed to better identify the critical isthmus and the exit of the circuit.\textsuperscript{24,94} In a recent study, a functional substrate map that examines propagation during sinus rhythm for wavefront discontinuities and conduction slowing was shown to identify regions that are critical for reentry. This novel voltage-independent,
high-density mapping display can demonstrate the functional substrate for VT during sinus rhythm and guide targeted ablation (Supplemental Video 2).95

Endocardial ablation has remained the initial approach since new developments in catheter ablation technology (ie, open irrigation and contact force sensing), and larger and deeper lesions can be created from the endocardial surface that can reach even an epicardial substrate. However, in some patients, the segmental lesion is intramural, and the circuit is predominantly kept by subepicardial fibers. Therefore, endocardial radiofrequency applications may not reach the intramyocardial and subepicardial fibers involved in the reentrant circuit. The transthoracic epicardial approach has been used since 1995 for mapping and ablation of sustained VT in patients with CCC and subsequently has also been applied in patients with other heart diseases.96

Recent studies have shown that a VT ablation strategy with a combined endo-epicardial approach in patients with CCC significantly reduces the recurrence of ventricular arrhythmias, without an increase in perioperative complications when performed by experienced groups (Figure 6).24,27,97–100 In a recent randomized controlled study, the efficacy and safety of an endo-epicardial ablation approach (group 1) vs an endocardial approach (group 2) were evaluated in patients with CCC associated with VT. In group 1, nonreinducibility of arrhythmia was achieved in 86% compared to 60% in group 2. At follow-up, 40% of patients in group 1 had VT recurrence compared to 80% in group 2. Some patients in group 2 with recurrence due to VT underwent an epicardial approach. There were no differences in the safety of the procedure between the 2 groups.101 During epicardial mapping, it is important to routinely identify areas where stimulation results in capture of the phrenic nerve to better define the substrate modification strategy and avoid phrenic nerve paralysis. Due to the frequent close distribution to the scar region to the circumflex coronary artery and its marginal branches, it is recommended to place the ablation catheter in the area related to the critical isthmus at the level of the epicardium and perform coronary angiography in the left and right anterior oblique projections before proceeding with the ablation. Catheter orientation aiming at the epicardium and not to the parietal pericardium is of critical importance to avoid damage to extracardiac structures.24,102,103

Other therapies
Radiofrequency ablation is one of the strategies used in patients with VT refractory to antiarrhythmic management; however, the success rate and long-term results remain suboptimal. For this reason, it is convenient to have other
therapeutic alternatives. One of these strategies is neuraxial modulation, in order to reduce sympathetic tone. One method is thoracic epidural anesthesia that results in block at the T1–T5 level, which is not selective and affects both the afferent and efferent signals. This option usually is utilized as a bridge to definitive measures and can be effective in up to 75%–80% of cases, with a quick onset of action and easy access.

Injection of local anesthetics into the stellate ganglion is available to temporarily block the lower third of the ganglion. This strategy is acutely effective in up to 90% of cases by reducing sympathetic impulses in the heart and in the head, neck, and diaphragm.

Another option is cardiac surgical denervation, a procedure that involves removing the lower part of the stellate ganglion and the T2–T4 nodes.

Conclusion
Ventricular arrhythmias are life-threatening complications of CCC and result in increased morbidity and mortality. SCD
due to malignant ventricular arrhythmias remains a public health problem in Latin America. Due to global migration, CCC is an emerging health problem in other regions. Ventricular arrhythmias are more common with advanced forms of cardiomyopathy, but it also can occur as the first manifestation of cardiac involvement. Identifying high-risk patients who require specific therapies and invasive procedures (ICD implantation, ablative therapies, neuraxial modulation) remains an important challenge in clinical practice. The presence of areas of fibrosis, autonomic dysfunction, and chronic inflammation contribute to the development of VT. An interesting feature of CCC is that fibrosis and scar can be more prominent in the epicardium than in the endocardium. A combined endo-epicardial approach significantly reduces the recurrence of ventricular arrhythmias, without increasing the rates of perioperative complications when performed by experienced groups. Alternative therapies such as neuraxial modulation and cardiac surgical denervation have shown a potential benefit in patients with VT recurrence after ablation.

**Funding Sources**
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Disclosures**
Dr Mario D. González is an advisor to Biosense Webster and Johnson & Johnson. All other authors report no conflicts of interest for the published content.

**Authorship**
All authors attest they meet the current ICMJE criteria for authorship.

**Appendix**
**Supplementary data**
Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hroo.2021.10.010.
References

1. World Health Organization. Chagas disease in Latin America: an epidemiologic update based on 2010 estimates. WHO Epidemiol Rec 2015;90:33–43.

2. World Health Organization. Control of Chagas disease: second report of the WHO expert committee World Health Organization (2000: Brasilia, Brazil) 905. Geneva World Health Organization; 2002. p. 1–109.

3. Bern C, Kjos S, Yabsley MJ, et al. Trypanosoma cruzi and Chagas’ disease in the United States. Clin Microbiol Rev 2011;24:655–681.

4. Canet PY, Stanier SL, Townsend RL, et al. The United States Trypanosoma cruzi infection study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion 2012;52:1922–1930.

5. Nunes M, Beaton A, Acquatella H, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation 2018;138:169–209.

6. Gascon J, Bern C, Pinzano MF. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010;115:22–29.

7. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009;49:52–56.

8. Rassi A, Marin-Neto A. Seminar Chagas disease. Lancet 2010;375:1388–1402.

9. Pinheiro de Andrade J, Marin-Neto J, Vincenzo AA, et al. I Directriz Latinoamericana para el Diagnóstico y Tratamiento de la Cardiopatía Chagásica. Arg Bras Cardiol 2011;96:434–442.

10. Rodríguez J, Albajar P. Chagas disease: a new worldwide challenge. Nature Rev Cardiol 2017;14:1510–1524.

11. Moncayo A, Silveira AC. Current epidemiological trends of Chagas disease in Latin America and future challenges: epidemiology, surveillance, and health policies. Mem Inst Oswaldo Cruz 2009;104(Suppl I):17–30.

12. Bocchi EA, Bestetti RB, Scanavacca MI, et al. Chronic Chagas heart disease management: from etiology to cardiomypathy treatment. J Am Coll Cardiol 2017;70:1510–1524.

13. Rassi AJ, Rassi A, Marin-Neto JA. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz 2009;104:152–158.

14. Marin-Neto JA, Cunha-Neto E, Maccê BC, et al. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109–1132.

15. Rossi M. Patterns of myocardial fibrosis in idiopathic cardiomyopathies and chronic Chagasic cardiopathy. Can J Cardiol 1991;7:287–294.

16. Amorim D, Marin-Neto JA. Functional alterations of the autonomic nervous system in Chagas’ heart disease. São Paulo Med J 1995;113:772–784.

17. De Alencar M, Da Costa M, De Oliveira M, et al. Heart rate recovery in asymptomatic patients with Chagas disease. PLoS One 2014;9:1–9.

18. Ribeiro A, Moraes R, Ribeiro J, et al. Parasympathetic dysautonomia left ventricular systolic dysfunction in Chagas disease. Am Heart J 2001;141:265–266.

19. Marín-Neto J, Simões M, Rassi A. Pathogenesis of chronic Chagas cardiomyopathy: the role of coronary microvascular derangements. Rev Soc Bras Med Trop 2013;46:536–541.

20. Morris SA, Tanowitz HB, Wittner M, et al. Pathophysiological insights into the cardiomyopathy of Chagas’ disease. Circulation 1990;82:1900–1909.

21. Castro R, Kuschin E, Sgammini H. Evaluación de la performance cardíaca y perfusión miocárdica con radiotrazadores en la cardiopatía chagásica crónica. Rev Fed Arg Cardiol 1988;17:226–231.

22. Rossi MA, Tanowitz HB, Malvestio LM, et al. Coronary microvascular disease in chronic chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms. PLoS Negl Trop Dis 2010;4:1–12.

23. Tortes FW, Acquatella H, Condado JA, et al. Coronary vascular reactivity is abnormal in patients with Chagas’ heart disease. Am Heart J 1995;129:905–1001.

24. Pisani C, Scanavacca MDA, D’Avila A, Cardiac mapping and imaging in patients with ventricular arrhythmias in Chagas disease undergoing catheter ablation of ventricular tachycardia. In: Shenasa M, Hindricks G, Callans D, Miller J, eds. Cardiac Mapping, Fifth Edition. Oxford, UK: John Wiley & Sons Ltd; 2019. p. 960–969.

25. Higuchi M, Benvenuti LA, Reis M, et al. Pathophysiology of the heart in Chagas’ disease: current status and new developments. Cardiovasc Res 2003;60:96–107.

26. Factor SM, Cho S, Wittner M, et al. Abnormalities of the coronary microcirculation in acute murine Chagas’ disease. Am J Trop Med Hyg 1985;34:246–253.

27. Henz B, Do Nascimento T, Dietrich C, et al. Simultaneous epicardial and endocardial substrate mapping and radiofrequency catheter ablation as first-line treatment for ventricular tachycardia and frequent ICD shocks in chronic chagasic cardiomyopathy. J Interv Card Electrophysiol 2009;26:195–205.
55. Tassi E, Continenzo M, do Nascimento E, et al. Relação entre fibrose e arritmias ventriculares na cardiopatia chagásica sem disfunção ventricular. Arq Bras Cardiol 2014;102:456–463.

56. Rochitte C, Oliveira P, Andrade J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol 2005;46:833–841.

57. Fernández-Armesto J, Bernotoo A, Andreu D, et al. Three-dimensional architecture of scar and conducting channels based on high resolution ce-CMR: insights for ventricular tachycardia ablation. Circ Arrhythm Hypertrophy 2013: 6:528–537.

58. De Mello R, Searf G, Schwartzman P, et al. Delayed enhancement cardiac magnetic resonance imaging can identify the risk for ventricular tachycardia in Chagas’ cardiomyopathy. Am J Cardiol 2012;98:421–430.

59. Volpe G, Moreira H, Traj H, et al. Left ventricular scar and prognosis in chronic Chagas cardiomyopathy. J Am Coll Cardiol 2018;72:2567–2576.

60. De Paola A, Horowitz L, Miyamoto M, et al. Angiographic and electrophysiological substrates of ventricular tachycardia in chronic chagasic myocarditis. Am J Cardiol 1999;65:360–363.

61. Sturrock E, Martinelli M, Sampaio R, et al. Sudden cardiac death in patients with chagas heart disease and preserved left ventricular function. J Cardiovasc Electrophysiol 2006;17:131–119.

62. Gadioli L, Miranda C, Pintya A, et al. The severity of ventricular arrhythmia correlates with the extent of myocardial sympathetic denervation, but not with myocardial fibrosis extent in chronic Chagas cardiomyopathy: Chagas disease, denervation and arrhythmia. J Nucl Cardiol 2018;25:75–83.

63. Miranda C, Figueredo A, Maciel B, et al. Sustained ventricular tachycardia is associated with regional myocardial sympathetic denervation assessed with 123I-metaiodobenzylguanidine in chronic Chagas cardiomyopathy. J Nucl Med 2011;52:504–514.

64. Cucunubi Z, Okawoga O, Basáñez M, et al. Increased mortality attributed to Chagas disease: a systematic review and meta-analysis. Parasit Vectors 2016; 9:1–13.

65. Ayub-Ferreira S, Mangini S, Issa V, et al. Mode of death on Chagas heart disease. Arq Bras Cardiol 2018;102:239–247.

66. Al-Khatib S, Stevenson W, Ackerman M, et al. 2017 AHA/ACC/HRS Guideline for the Evaluation and Management of Patients With Cardiac Arrhythmias. J Am Coll Cardiol 2017;69:e129–e2185.

67. Altcheh J, Biancardi M, Lapen A, et al. Zn2+, Fe2+, and Cu2+ ion concentrations in the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents 2012;40:514–518.

68. Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi. arQ bras cardiol 2014;102:524–532.

69. Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas heart disease. Arzneimittelforschung 1972;22:1624–1629.

70. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for treatment of sustained ventricular arrhythmias in patients with Chagas cardiomyopathy: the REMADHE trial. Circ Heart Fail 2018;11:129–136.

71. Issa V, Amaral A, Cruz F, et al. Ventricular tachycardia ablation. Circ Arrhythmia Electrophysiol 2013; 6:528–537.

72. Freitas H, Chizzola P, Paes-Z, Okuwoga O, Basáñez M, et al. Long-term prospective, randomized, controlled study using repetitive education at six-month intervals and monitoring for adherence in heart failure outpatients: the REMADHE trial. Circ Heart Fail 2008;1:115–124.

73. Altcheh J, Biancardi M, Laperia A, et al. Congenital Chagas disease: experience in the Hospital de Niños, Buenos Aires, Argentina. Rev Soc Bras Med Trop 2005;38:41–46.

74. Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chag as. PLoS Negl Trop Dis 2014;8:1–9.

75. Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas’ infection. Arzneimittelforschung 1972;22:1624–1635.

76. Marrolo CA, Marin-Neto JA, Araujo A, et al. Randomized trial of benznidazole for Chagas’ cardiomyopathy. N Engl J Med 2015;373:1295–1306.

77. Issa V, Amaral A, Cruz F, et al. β-Blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail 2010;3:82–90.

78. Roche-Crosby S, Mangini S, Issa V, et al. Mode of death on Chagas heart disease: comparison with other etiologies. A subanalysis of the REMADHE prospective trial. Circ Heart Fail 2007;1:110–119.

79. De Souza ACJ, Salles G, Hasslocher-Moreno AM, et al. Development of a risk score to predict sudden death in patients with Chagas’ heart disease. Int J Cardiol 2015;187:700–704.

80. Di Lorenzo C, Nunes MC, Colosimo EA, et al. Risk score for predicting 2-year mortality in patients with Chagas cardiomyopathy from endemic areas: SAMIT Troph Cohort Study. J Am Heart Assoc 2020;9:1–13.

81. McDonagh T, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–3737.

82. Lourenço AM, Castro C, Costa C, et al. Evaluation of in vitro anti-Trypanosoma cruzi activity of medications benznidazole, amiodarone hydrochloride, and their combination. Rev Soc Bras Med Trop 2018;51:52–56.
101. Pisani C, Romero J, Lara S, et al. Efficacy and safety of combined endocardial/epicardial catheter ablation for ventricular tachycardia in Chagas disease: a randomized controlled study. Heart Rhythm 2020;17:1510–1518.

102. Aryana A, D’Avila A. Epicardial catheter ablation of ventricular tachycardia. Card Electrophysiol Clin 2017;9:119–131.

103. Aryana A, D’Avila A. Contact force during VT Ablation: vector orientation is key. Circ Arrhythmia Electrophysiol 2014;7:1009–1019.

104. Kumar S, Tedrow UB, Stevenson WG. Adjunctive interventional techniques when percutaneous catheter ablation for drug refractory ventricular arrhythmias fail: a contemporary review. Circ Arrhythmia Electrophysiol 2017;10:1–12.

105. Romero J, Velasco A, Pisani CF, et al. Advanced therapies for ventricular arrhythmias in patients with Chagasic Cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2021;77:1225–1242.

106. Santos M, Leite L, Macedo P, et al. Left Cardiac sympathetic denervation for patients with malignant ventricular tachycardia in Chagas DISEASE—preliminary results of DESERT Study. Circulation 2013;128:A17450.

107. Meng L, Tseng C, Shivkumar K. Efficacy of stellate ganglion blockade in managing electrical storm. JACC Clin Electrophysiol 2017;3:942–951.

108. Saenz LC, Corrales FM, Bautista W, et al. Cardiac sympathetic denervation for intractable ventricular arrhythmias in Chagas disease. Heart Rhythm 2016;13:1388–1394.